Status:
COMPLETED
Hemocontrol and Blood Pressure Control in Dialysis Patients
Lead Sponsor:
Université de Montréal
Collaborating Sponsors:
Gambro Renal Products, Inc.
Conditions:
End-Stage Renal Disease
Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Volume overload contributes significantly to the pathogenesis of hypertension in hemodialysis patients. The Hemocontrol(HC)system (Gambro), which automatically adjusts ultrafiltration rate and dialysa...
Detailed Description
Hypertension is a common problem in patients undergoing chronic maintenance hemodialysis (HD) with a reported prevalence of 50 to 90 % \[Hörl, 2002\]. As a major risk factor for cardiovascular disease...
Eligibility Criteria
Inclusion
- 18 years or older
- chronic hemodialysis
- on renal replacement therapy \> 3 months
- at least 3 dialysis sessions and 9 hours of therapy weekly
- willing to measure blood pressure at home
- able to sign an informed consent
Exclusion
- anticipated change in renal replacement therapy
- anticipated transfer to another center
- planned renal transplantation
- enrollment in another clinical trial
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2003
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00319774
Start Date
December 1 2002
End Date
July 1 2003
Last Update
April 27 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada, H4J 1C5